BioMarin Pharmaceutical Inc

BMRN 
(NASDAQ) 
 
$ 78.22 <%= Resources.Global.txtUp %>
Updated 20/08/2019
Change % 2.24% Stock price increasing
Change 1.71 Stock price increasing
Volume 761,778
High $ 78.74
Low $ 76.26
Open $ 77.07
ISIN
Prev close $ 76.51
# of shares 179.46M
Market cap 14,038M USD
Intraday

Market closed
BioMarin Pharmaceutical Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  78.22 9.0% Stock price increasing -4.1% Stock price decreasing -10.8% Stock price decreasing -11.0% Stock price decreasing -23.0% Stock price decreasing
Powered by TradingView

Company profile

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 August 2019 00:13:00
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB4 - 2019-08-22 01:13:00 - 2019-08-22 00:13:00 - 1000 - Website: OKAY